Ranok Therapeutics Co., Ltd, a Hangzhou-based biotech firm, announced that the first patient has been dosed in the Phase I/II CHAMP-1 study (NCT05487170) of its lead drug candidate RNK05047 in the United States. The trial will evaluate the safety and optimal dosage of the potential first-in-class small-molecule degrader targeting BRD4 in solid tumors and diffuse large B-cell lymphoma (DLBCL).
Drug Profile
RNK05047, discovered via Ranok’s proprietary CHAMP protein degradation platform, is designed to degrade BRD4, a key regulator of oncogenes such as MYC and BCL2. The molecule’s novel mechanism aims to address unmet needs in cancer treatment by targeting BRD4’s role in tumor development.
Study Details
The CHAMP-1 study will assess RNK05047’s safety and tolerability, with preliminary data expected in Q2 2023. The trial’s success could pave the way for further development of BRD4-targeted therapies in oncology.-Fineline Info & Tech
